Nearly 5.4 million cancer survivors suffer chronic pain

June 20, 2019

A new report finds about one in three cancer survivors (34.6%) reported having chronic pain, representing nearly 5.4 million cancer survivors in the United States. The report, appearing as a Research Letter in JAMA Oncology, finds one in six survivors (16%), representing about 2.5 million people in the U.S., reported suffering from high impact chronic pain that restricts daily functioning. Those rates are about double the rates in the general population.

Chronic pain is one of the most common long-term effects of cancer treatment and has been linked with an impaired quality of life, lower adherence to treatment, and higher health care costs. Nevertheless, there is a paucity of information regarding the prevalence of, and risk factors for, the development of chronic pain among cancer survivors.

To gain a better understanding of the epidemiology of pain in cancer survivors and help inform future health care priorities and policies, investigators led by Changchuan (Charles) Jiang, MD MPH of Mount Sinai St. Luke's and Mount Sinai West, New York, with researchers from Memorial Sloan-Kettering Cancer Center, University of Virginia, and the American Cancer Society investigated the prevalence of chronic pain among cancer survivors in the United States using data from the National Health Interview Survey (2016-2017). The survey collects information related to chronic pain (pain on most days or every day in the past six months) and high impact chronic pain (chronic pain limiting life or work activities on most days or every day in the past 6 months).

Overall, 1,648 of the 4,526 cancer survivors identified in the survey (34.6%) reported having chronic pain; 768 of the survivors (16.1%) reported having high impact chronic pain. Applied to the nation as a whole, those rates equal approximately 5.39 million and 2.51 million cancer survivors, respectively, in the U.S.

Time since diagnosis was not significantly associated with the prevalence of either chronic pain, but a higher prevalence of chronic and high impact chronic pain was reported among survivors with less than a high school education (39.2% for chronic pain and 18.5% for high impact chronic pain), low household income (44.6% and 22.8%, respectively), public insurance among those aged 18-64 years (43.6% and 27.1%, respectively), or no paid employment (38.5% and 20.4%, respectively).

"Because socioeconomic status and employment are associated with insurance coverage and access to care in the United States, the patterns of chronic pain that we observed in cancer survivors may be explained by barriers to cancer care and pain management as well as by the type and extent of cancer treatment received," said Xuesong Han, PhD, American Cancer Society investigator and co-author of the report. "The prevalence of chronic pain and high impact chronic pain among cancer survivors in our study was almost double that in the general population, suggesting there are important unmet needs in the large and growing community of people with a history of cancer."
-end-
Article: Prevalence of Chronic Pain and High-Impact Chronic Pain in Cancer Survivors in the United States; Jiang et al.; JAMA Oncology; Published online June 20, 2019; doi:10.1001/jamaoncol.2019.1439

Article: Prevalence of Chronic Pain and High-Impact Chronic Pain in Cancer Survivors in the United States; Jiang et al.; JAMA Oncology; Published online June 20, 2019; doi:10.1001/jamaoncol.2019.1439

URL after embargo: https://jamanetwork.com/journals/jamaoncology/fullarticle/2736363

American Cancer Society

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.